Fenwick & West represented Day One Biopharmaceuticals in the transaction. Day One Biopharmaceuticals (Nasdaq: DAWN) (“Day One”), a commercial-stage biopharmaceutical company announced its exclusive licensing agreement...
Day One Biopharmaceuticals’ License Agreement with MabCare Therapeutics
Sutro Biopharma’s Option Grant Agreement with Vaxcyte
Fenwick represented Sutro Biopharma on the deal. Sutro Biopharma (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), announced its option grant...
Sutro Biopharma’s Strategic Collaboration with Astellas
Fenwick represented Sutro Biopharma, Inc. on the deal. Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage oncology company, announced its strategic collaboration and licensing agreement with Astellas Pharma...
Day One Biopharmaceuticals’ Licensing Agreement with Merck KGaA
Fenwick & West LLP advised Day One Biopharmaceuticals on the deal. Day One Biopharmaceuticals, a clinical-stage biopharmaceutical company focused on accelerating new targeted therapies for children...